Experts discussed the development potential of the pharmaceutical industry in the light of Pharma-2030 strategy
In the framework of “Pharma-2030 Strategy: renewal effect” session of the international conference “Pharma Business in Russia – 2021” moderated by Vladislav Shestakov, Director of SID&GP, the participants discussed topical issues of pharmaceutical industry development for the last ten years and identified goals to be set for the industry in the light of Pharma-2030 strategy.
The session was opened by Aleksey Alekhin, Advisor to the Minister of Industry and Trade of the Russian Federation, who outlined the main directions of further development of the pharmaceutical industry: from saturation of the Russian market with local pharmaceutical products to entering foreign markets.
“Pharma-2030 strategy is designed to answer the question of how and what should be done to reduce the level of morbidity and mortality in certain nosologies, which are currently a priority, and at the same time create those products that will be in demand in other countries. Our pharma has huge export potential, we are competent and can show the entire global community that our developers and our level of manufacturing deserve public recognition,” Aleksey Alekhin summed up in his speech.
Representatives of pharmaceutical business – companies “Nanolek”, “Geropharm” and “Active Component” – noted that the state program “Pharma-2020” gave a huge boost to the development of the Russian pharmaceutical industry, and state support of manufacturers has brought Russian pharmaceutical manufacturing to the world level, that made it possible to compete with foreign manufacturers and won recognition and trust of Russian patients. Separately, the issues of providing Russian pharmaceutical manufacturing with active pharmaceutical substances were touched upon.
“In 2019, the issue of creating our own database of reference standards was already raised,” continuing the topic of API and standard samples, said Vladislav Shestakov, Director of the SID&GP. – Signals about the need to create our own database of reference standards were already there, and with the pandemic arrival, the risks of the lack of such a base became obvious to all market participants.”
In February 2020, the creation of the “National Center for Reference Standards” under SID&GP was a strategically and tactically important task for the Russian pharmaceutical industry. In a year of work, the Center began to create a base of Reference Standards, registered a number of Reference Standards and outlined ambitious goals for the near future: assortment expansion and international expansion.
Following the discussion on key directions of the pharmaceutical industry, the participants of session “Strategy Pharma – 2030: renewal effect” turned to issues pertinent to human resources of the industry. Considering the tasks faced by the industry, and particularly the mission of moving the pharmaceutical sphere towards the innovation-based model of development, in times when the growth and opening of new manufacturing sites, and development of scientific activities are becoming more permanent, a routine practice, and not an exceptional event, the issue regarding the availability of qualified personnel that would meet the requirements of manufacturing companies, becomes more acute day by day.
“We ought to have some educational ecosystem in place, which could unite all stakeholders in the pharmaceutical sector, – said in her speech Natalia Pyatigorskaya, Deputy director for science of Institute of translational medicine and biotechnology of Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). – Today the traditional education tends to disappear and ceases to become relevant. The market is seeing the entry of graduates, who are not familiar with practical skills, hands-on preparation”.
This topic was actively uphold and developed by Zakhar Golant, chairman of the Board, Union of Pharmaceutical and Biomedical Clusters of Russia. “Clearly, I am ready to support the thesis regarding ecosystem. What is an educational standard in isolation from industry? It is some form, which in itself is without contents. The content can be given by that industry, which sets its own standards: what level of specialists is required, what skills and qualifications must they have?”.
On the whole, Zakhar Golant noted the key centers of excellence, or pharmaceutical clusters, were formed in those places, where there was good investment policy, where regions supported and rapidly faciliated engineering networks, plots of land. And first and foremost, the regions that received development, were the ones with good educational base and where the programs for training competent specialists were implemented.
In concluding the dialogue, the session moderator Vladislav Shestakov noted that within “Pharma 2020”, which has been extended for three more years, the Russian pharmaceutical industry has made significant progress.
“Russian companies have all the competencies and technological capabilities to establish effective competition with foreign pharmaceutical manufacturers. Import substitution policy clearly demonstrates that. And now we need all the resources for development the domestic industry, including innovative technologies and products for ensuring drug security of the country, and also for the development of export”, – summarized the session Vladislav Shestakov.
- Cooperation issues in the pharmaceutical industry and healthcare system were discussed at the Russia-Africa Summit
- International cooperation discussed at the Drug Safety Forum
- Transformation of medical education and training of highly qualified personnel discussed at the Uzbek-Russian Medical Forum
- Memorandum of Cooperation signed between the Eurasian Academy of Good Practices, State Center for Expertise and Standardization of Medicines, Medical Devices and Medical Equipment (Uzbekistan), and Rusatom Healthcare JSC
- The prospects for the development of cooperation between Russia and Saudi Arabia in the pharmaceutical industry were discussed as part of the business mission Made in Russia + INNOPROM